Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.

2.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

3.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium.

J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

PMID:
22850121
4.

Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.

Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium.

Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. doi: 10.5588/ijtld.11.0548.

PMID:
22325844
5.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

6.

Relative burden of large CNVs on a range of neurodevelopmental phenotypes.

Girirajan S, Brkanac Z, Coe BP, Baker C, Vives L, Vu TH, Shafer N, Bernier R, Ferrero GB, Silengo M, Warren ST, Moreno CS, Fichera M, Romano C, Raskind WH, Eichler EE.

PLoS Genet. 2011 Nov;7(11):e1002334. doi: 10.1371/journal.pgen.1002334. Epub 2011 Nov 10.

7.

Copy number variation analysis in single-suture craniosynostosis: multiple rare variants including RUNX2 duplication in two cousins with metopic craniosynostosis.

Mefford HC, Shafer N, Antonacci F, Tsai JM, Park SS, Hing AV, Rieder MJ, Smyth MD, Speltz ML, Eichler EE, Cunningham ML.

Am J Med Genet A. 2010 Sep;152A(9):2203-10. doi: 10.1002/ajmg.a.33557.

8.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium.

PLoS One. 2010 May 20;5(5):e10753. doi: 10.1371/journal.pone.0010753.

9.

A method for rapid, targeted CNV genotyping identifies rare variants associated with neurocognitive disease.

Mefford HC, Cooper GM, Zerr T, Smith JD, Baker C, Shafer N, Thorland EC, Skinner C, Schwartz CE, Nickerson DA, Eichler EE.

Genome Res. 2009 Sep;19(9):1579-85. doi: 10.1101/gr.094987.109. Epub 2009 Jun 8.

10.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.

PMID:
19406981
11.

Physical activity and exercise training prescriptions for patients.

Foster C, Cadwell K, Crenshaw B, Dehart-Beverley M, Hatcher S, Karlsdottir AE, Shafer NN, Theusch C, Porcari JP.

Cardiol Clin. 2001 Aug;19(3):447-57. Review.

PMID:
11570116
12.
13.

State-to-State Rates for the D + H2(v = 1, j = 1) rarr HD(v', j') + H Reaction: Predictions and Measurements.

Neuhauser D, Judson RS, Kouri DJ, Adelman DE, Shafer NE, Kliner DA, Zare RN.

Science. 1992 Jul 24;257(5069):519-22.

PMID:
17778685
14.

Erratum: Photoionization cross section of hydrogenic atoms: A generating function solution

Shafer N, Bersohn R.

Phys Rev A. 1991 Dec 1;44(11):7855. No abstract available.

PMID:
9920605
15.
16.

Photoionization cross section of hydrogenic atoms: A generating function solution.

Shafer N, Bersohn R.

Phys Rev A. 1990 Aug 1;42(3):1313-1317. No abstract available.

PMID:
9904157
17.

[Plasma levels of endogenous opioid peptides in patients with chronic colitis].

Shafer NP.

Klin Med (Mosk). 1989 Oct;67(10):101-3. Russian.

PMID:
2533304
18.

Cafe coronary: recognition, treatment and prevention.

Kitay G, Shafer N.

Nurse Pract. 1989 Jun;14(6):35-8, 43, 46.

PMID:
2739952
19.

Cancer of the colon: medicolegal considerations.

Shafer N, Kitay G.

Leg Med. 1989:113-24. Review. No abstract available.

PMID:
2700003
20.

Transcutaneous electrical nerve stimulation and pain relief: an overview.

Shafer N, Kitay G.

Med Electron. 1988 Oct;19(5):132-6. Review.

PMID:
10302874

Supplemental Content

Loading ...
Support Center